GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (OTCPK:ENTBF) » Definitions » Interest Expense

Entheon Biomedical (Entheon Biomedical) Interest Expense : $0.00 Mil (TTM As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Entheon Biomedical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Entheon Biomedical's interest expense for the three months ended in Feb. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Entheon Biomedical's Operating Income for the three months ended in Feb. 2024 was $ -0.06 Mil. Entheon Biomedical's Interest Expense for the three months ended in Feb. 2024 was $ 0.00 Mil. Entheon Biomedical has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Entheon Biomedical Interest Expense Historical Data

The historical data trend for Entheon Biomedical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Interest Expense Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Interest Expense
Get a 7-Day Free Trial -0.01 - - - -

Entheon Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Entheon Biomedical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical  (OTCPK:ENTBF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Entheon Biomedical's Interest Expense for the three months ended in Feb. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Feb. 2024 was $-0.06 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2024 was $0.00 Mil.

Entheon Biomedical's Interest Coverage for the quarter that ended in Feb. 2024 is calculated as

Entheon Biomedical had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Entheon Biomedical Corp has no debt.

Entheon Biomedical (Entheon Biomedical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (OTCPK:ENTBF) » Definitions » Interest Expense
Comparable Companies
XCNQ:MYND XCNQ:ABRT XCNQ:WESA.X TSXV:BTI XCNQ:HAVN TSXV:IBO XCNQ:GTTX TSXV:APC.H XCNQ:MOOD XCNQ:NSHS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
1XU1:Germany ENBI:Canada
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Website
https://www.entheonbiomedical.com
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.